Search

Displaying results 1901 - 1910 of 6949 in total
  1. Drug

    Chromium picolinate

    go.drugbank.com/drugs/DB11255
    Approved

    Chromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss. … Chromium ions are shown to regulate insulin by promoting glucose utilization and increasing the sensitivity of the insulin receptor [A27235].

    Mixtures: BLACKMORES teen multi for GUYS capsule
  2. Drug

    Fluoroestradiol F-18

    go.drugbank.com/drugs/DB15690
    ApprovedInvestigational

    across metastases (i.e. to identify sites that no longer express ER) without the need for multiple biopsies. … [L14096] The ability to image ER-positive tumors _in vivo_ is advantageous in that, while helping to visualize tumor progression/regression, it may also be used to assess for heterogeneity in ER expression

  3. Drug

    Celiprolol

    go.drugbank.com/drugs/DB04846
    ApprovedInvestigationalWithdrawn

    Celiprolol is not approved for use by the FDA in the treatment of vascular Ehlers–Danlos syndrome. … Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris.

    Categories: Adrenergic beta-2 Receptor Agonists, Adrenergic beta-3 Receptor Agonists
  4. Drug

    Betibeglogene autotemcel

    go.drugbank.com/drugs/DB16900
    ApprovedInvestigational

    [L42940] BB305 LVV encodes β<sup>A-T87Q</sup>-globin, compensating for the lack of β-globin in these patients. … This affects hemoglobin levels, and in patients with severe forms of this disease, long-term red cell transfusions are required for survival and the prevention of serious complications.

  5. Drug

    Pegulicianine

    go.drugbank.com/drugs/DB18731
    ApprovedInvestigational

    [L50537] Pegulicianine (under the brand name Lumisight) was approved for use by the FDA in April 2024.[L50537,L50547] It received Fast Track and priority review for this indication.[L50547] … Pegulicianine is an optical imaging agent indicated for fluorescence imaging in patients with breast cancer.

  6. Drug

    Trihexyphenidyl

    go.drugbank.com/drugs/DB00376
    ApprovedInvestigational

    [L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. … Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.

    International brands: Atan
  7. Drug

    Hexylresorcinol

    go.drugbank.com/drugs/DB11254
    Approved

    It can be found in topical applications for minor skin infections and in oral solutions or throat lozenges for pain relief and first aid antiseptic.

  8. Drug

    Onasemnogene abeparvovec

    go.drugbank.com/drugs/DB15528
    ApprovedInvestigational

    Onasemnogene abeparvovec is the first gene therapy that was approved for this indication in the USA. … [Nusinersen] is another gene therapy that is currently approved by the FDA for the treatment of SMA in pediatric and adult patients.

  9. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate … [L52230] It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase.

  10. Drug

    Tralokinumab

    go.drugbank.com/drugs/DB12169
    ApprovedInvestigational

    Tralokinumab was first approved for the treatment of atopic dermatitis by the EMA in June 2021, under the brand name Adtralza (Leo Pharma), and was subsequently approved in Canada in October 2021 and the

    Categories: Agents for Dermatitis, Excluding Corticosteroids